On January 5, 2026, Catherine A. Sohn, a member of Altimmune's board, purchased an additional 500 shares of common stock, raising her total ownership to 1,500 shares. This insider purchase underscores growing confidence in the company's lead program and provides a signal to the market that management is aligned with shareholder interests as Altimmune advances its therapeutic candidates.

The U.S. Food and Drug Administration has awarded Breakthrough Therapy Designation to pemvidutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). This status is reserved for investigational agents that demonstrate the potential for substantial improvement over existing therapies for serious conditions and promises an expedited review pathway and enhanced regulatory engagement.

Altimmune reported 48-week Phase IIb results for pemvidutide showing dose-dependent, durable improvements in noninvasive fibrosis markers and a favorable safety profile. Patients receiving the 1.8 mg dose achieved an average weight reduction of 7.5%, while key liver enzyme levels declined by a median of 30%, reinforcing the drug’s therapeutic potential ahead of a planned Phase III program.

With a market capitalization near $361 million and average daily trading volume of approximately 26.8 million shares, Altimmune is well positioned to fund its upcoming pivotal trial. The Phase III study will focus on biopsy-based endpoints and evaluate a 2.4 mg dose of pemvidutide under an accelerated approval framework, aiming to deliver a new option for patients with serious liver disease within the next two years.